Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment
Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone payment from Servier. The multi-targets oncology collaboration of both parties, announced in early 2026, carries a total value of up to $888 million with $32 million in upfront and near-term R&D payments.
CAMBRIDGE, Mass., Oct. 20, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative artificial…
Read the full report on Pr Newswire Apac
Story file
- Section
- Tech
- Topics
- Stock market, Startups, AI & gadgets, Farmers & agriculture
- First reported by
- Pr Newswire Apac
- Reporter
- cision pr newswire
- Published
- Tuesday, 20 October 2026, 6:30 pm IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Pr Newswire Apac with a short summary and a link to the original. The original reporting belongs to the publisher. Spotted an error in our summary? Tell our corrections desk.
